Due to the varying frequency of alterations between the parent and daughter cell lines within dysregulated PCa pathways, we treated the LNCaP family cell lines with the PARP inhibitor olaparib, PI3K inhibitors alpelisib and GDC-0077, and AKT inhibitors ipatasertib, capivasertib, and A-674563. This evidence concerns the gene PIK3CA and posterior cortical atrophy.